During Q4 2018 the big money sentiment increased to 1.21. That’s change of 0.07, from 2018Q3’s 1.14. 32 investors sold all, 59 reduced holdings as Integra LifeSciences Holdings Corporation ratio is positive. 74 grew stakes while 36 funds acquired stakes. Funds hold 70.91 million shares thus 1.24% less from 2018Q3’s 71.80 million shares.
Cap Investors reported 2.13 million shs or 0.05% of all its holdings. Quantitative Invest Mngmt Limited Liability Co reported 0.05% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Gideon Cap Incorporated owns 0.19% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 10,442 shs. Natixis Limited Partnership has 0.03% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART). State Bank Of Montreal Can invested in 0% or 13,648 shs. 387,119 were accumulated by Royal Commercial Bank Of Canada. Ameritas Investment Prns invested in 20,862 shs or 0.05% of the stock. Fisher Asset Management Limited Com holds 945,619 shs. Ww Investors invested in 0.01% or 1.14M shs. Marshall Wace Ltd Liability Partnership has 0.07% invested in Integra LifeSciences Holdings Corporation (NASDAQ:IART) for 143,426 shs. Next Fincl Group accumulated 251 shs. Huntington Bankshares holds 0% or 1,708 shs. Invesco Limited has invested 0.02% in Integra LifeSciences Holdings Corporation (NASDAQ:IART). Virginia Retirement Systems Et Al invested in 0.01% or 18,800 shs. Deutsche Savings Bank Ag owns 137,158 shs.

Investors wait Integra LifeSciences Holdings Corporation (NASDAQ:IART)’s quarterly earnings on April, 24., according to Faxor. Analysts have expectation on stock’s EPS of $0.61. That’s up 5.17 % from last year’s $0.58 EPS. This could hit $51.99 million profit for IART assuming the current $0.61 EPS will become reality. Last quarter $0.65 EPS was reported. Analysts forecasts -6.15 % negative EPS growth this quarter. IART touched $55.42 during the last trading session after $0.1 change.Currently Integra LifeSciences Holdings Corporation is uptrending after 8.33% change in last March 28, 2018. IART has also 141,056 shares volume. The stock outperformed the S&P500 by 3.96%.

Integra LifeSciences Holdings Corporation (NASDAQ:IART) Ratings Coverage

Total analysts of 11 have positions in Integra Lifesciences (NASDAQ:IART) as follows: 5 rated it a “Buy”, 0 with “Sell” and 6 with “Hold”. The positive are 45%. Since October 11, 2018 according to StockzIntelligence Inc Integra Lifesciences has 18 analyst reports. On Monday, March 11 the firm has “Buy” rating by Piper Jaffray given. On Thursday, February 21 the firm has “Buy” rating by BTIG Research given. On Monday, March 11 the stock of Integra LifeSciences Holdings Corporation (NASDAQ:IART) has “Hold” rating given by Cantor Fitzgerald. The company rating was maintained by Wells Fargo on Thursday, November 1. The company rating was maintained by JMP Securities on Tuesday, February 26. In Friday, February 22 report RBC Capital Markets maintained the stock with “Hold” rating. On Friday, February 22 the company was maintained by Citigroup. On Friday, February 22 the firm earned “Hold” rating by Morgan Stanley. The stock rating was maintained by Piper Jaffray with “Buy” on Thursday, February 21. On Friday, November 2 Citigroup maintained Integra LifeSciences Holdings Corporation (NASDAQ:IART) rating. Citigroup has “Neutral” rating and $60 target.

Integra LifeSciences Holdings Corporation develops, makes, and markets surgical implants and medical instruments for use in neurosurgery, extremity reconstruction, orthopedics, and general surgery.The company has $4.72 billion market cap. The firm operates through two divisions, Specialty Surgical Solutions; and Orthopedics and Tissue Technologies.The P/E ratio is 76.97. It offers neurosurgery and critical care products, including tissue ablation equipment, dural repair products, cerebral spinal fluid management devices, intracranial monitoring equipment, and cranial stabilization equipment.

For more Integra LifeSciences Holdings Corporation (NASDAQ:IART) news published recently go to: Globenewswire.com, Seekingalpha.com, Globenewswire.com, Seekingalpha.com or Globenewswire.com. The titles are as follows: “Integra LifeSciences to participate in the Cantor Global Healthcare Conference – GlobeNewswire” published on September 19, 2018, “Integra LifeSciences Holdings Corporation (IART) – Seeking Alpha” on January 10, 2019, “Integra LifeSciences Selected for Healogics iSupply Program – GlobeNewswire” with a publish date: September 10, 2018, “Credit Suisse sees 18% upside in Abbott in premarket analyst action – Seeking Alpha” and the last “Integra LifeSciences Announces the Approval of DuraGen® in Japan – GlobeNewswire” with publication date: March 14, 2019.